NEU 1.83% $12.90 neuren pharmaceuticals limited

st this next paragraph , explaining the Oral NNZ2566 Trials...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 10,009 Posts.
    st this next paragraph , explaining the Oral NNZ2566 Trials which should be completed in 18 Months time, if successful will create value far in Excess of todays market cap.

    Again fully funded and easy trials easy recruitment and low efficacy barrier.

    " planning to start a Phase II trial in Q4 this year, in time for high school and college football and soccer
    seasons in the US. The study will be led by the University of Pittsburgh Sports Medicine Concussion
    Program, one of the leading centers for research in concussion. The direct costs of the trial will be
    funded by the US Army which has committed approximately US$3.8m for the study and for
    development of NNZ-2566 oral. Patients enrolled in the trial will be athletes who are already enrolled
    in a screening program called Immediate Post-Concussion Assessment and Cognitive Testing or
    ImPACT®. People enrolled in ImPACT® have baseline, pre-injury neurocognitive assessments
    completed such that each subject will essentially serve as his or her own control. This design
    increases the statistical power and decreases sample size requirements, allowing us to use return to
    baseline as the measure of efficacy which is much more sensitive than comparison with normative,
    general population-based data.
    Potential subjects will be identified by personnel trained by the UPMC group at the sports field rather
    than waiting for them to show up at the emergency department. All patients will have an MRI with
    Diffusion Tensor Imaging or DTI to help identify patients with specific types of brain injury which will
    be part of the analysis at the end of the study. DTI is particularly useful for imaging injuries in the
    axons that make up the white matter of the brain. So-called diffuse axonal injury or axonal shearing
    often occurs as a consequence of acceleration – deceleration injuries which are common among
    athletes and blast-injured soldiers. We are forecasting that enrollment in the Phase II trial will be
    completed within a year."
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.